trending Market Intelligence /marketintelligence/en/news-insights/trending/piy1guz8byejrb-lelnghw2 content esgSubNav
In This List

Leap Therapeutics prices $14M common stock offering

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Leap Therapeutics prices $14M common stock offering

Leap Therapeutics, Inc. priced an underwritten public offering of 1,866,667 shares at $7.50 apiece to raise about $14 million in gross proceeds.

Raymond James & Associates Inc. and Ladenburg Thalmann are acting as book-running managers for the offering which is expected to close by March 27.

The Cambridge, Mass.-based biopharmaceutical company granted underwriters an option to buy up to an additional 280,000 shares.

The company plans to use the net proceeds for general corporate purposes, which may include funding new clinical trials of DKN-01 and TRX518.

DKN-01 is under development to treat patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers. TRX518 is an antibody designed to enhance the immune system's anti-tumor response.